Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Equivalents (2016 - 2025)

Regenxbio (RGNX) has 12 years of Cash & Equivalents data on record, last reported at $34.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 40.09% year-over-year to $34.5 million; the TTM value through Dec 2025 reached $34.5 million, down 40.09%, while the annual FY2025 figure was $34.5 million, 40.09% down from the prior year.
  • Cash & Equivalents reached $34.5 million in Q4 2025 per RGNX's latest filing, down from $58.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $345.2 million in Q4 2021 and bottomed at $34.5 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $123.2 million, with a median of $88.3 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: surged 319.94% in 2021, then tumbled 71.91% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $345.2 million in 2021, then crashed by 71.91% to $97.0 million in 2022, then plummeted by 64.39% to $34.5 million in 2023, then soared by 66.64% to $57.5 million in 2024, then tumbled by 40.09% to $34.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $34.5 million in Q4 2025, $58.8 million in Q3 2025, and $79.6 million in Q2 2025.